Central statistical monitoring of investigator-led clinical trials in oncology

被引:13
作者
Buyse, Marc [1 ,2 ,3 ]
Trotta, Laura [3 ]
Saad, Everardo D. [4 ]
Sakamoto, Junichi [5 ,6 ]
机构
[1] Int Drug Dev Inst IDDI, San Francisco, CA 94133 USA
[2] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Hasselt, Belgium
[3] CluePoints, Louvain La Neuve, Belgium
[4] Int Drug Dev Inst IDDI, 30 Ave Prov, B-1340 Ottignies, Belgium
[5] Tokai Cent Hosp, Kakamigahara, Japan
[6] Epidemiol & Clin Res Informat Network ECRIN, Kyoto, Japan
关键词
Investigator-led trials; Central statistical monitoring; Data quality; Trial costs; DATA QUALITY; SYSTEMS; COST;
D O I
10.1007/s10147-020-01726-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Investigator-led clinical trials are pragmatic trials that aim to investigate the benefits and harms of treatments in routine clinical practice. These much-needed trials represent the majority of all trials currently conducted. They are however threatened by the rising costs of clinical research, which are in part due to extensive trial monitoring processes that focus on unimportant details. Risk-based quality management focuses, instead, on "things that really matter". We discuss the role of central statistical monitoring as part of risk-based quality management. We describe the principles of central statistical monitoring, provide examples of its use, and argue that it could help drive down the cost of randomized clinical trials, especially investigator-led trials, whilst improving their quality.
引用
收藏
页码:1207 / 1214
页数:8
相关论文
empty
未找到相关数据